List of Savaysa drug patents
Savaysa is owned by Daiichi Sankyo Inc.
Savaysa contains Edoxaban Tosylate.
Savaysa has a total of 2 drug patents out of which 0 drug patents have expired.
Savaysa was authorised for market use on 08 January, 2015.
Savaysa is available in tablet;oral dosage forms.
The generics of Savaysa are possible to be released after 28 March, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7365205 | DAIICHI SANKYO INC | Diamine derivatives |
Apr, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9149532 | DAIICHI SANKYO INC | Pharmaceutical composition |
Mar, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Aug 9, 2022 |
Drugs and Companies using EDOXABAN TOSYLATE ingredient
Market Authorisation Date: 08 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of SAVAYSA before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic